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Background: Catheter-related bloodstream infections (CRBSI) with coagulase-negative Staphylococci (CoNS) are a
common source of hospital-acquired bloodstream infections. The main objective of this study was to elucidate the
role of systemic antibiotic therapy in the setting of catheter removal in adult patients with CoNS-CRBSI.
Methods: We conducted a retrospective cohort study on patients with CoNS-CRBSI diagnosed between 2008 and
2016 with follow-up for up to 12 months. The main inclusion criterion was a removed intravascular catheter with
quantitative catheter tip culture growing CoNS and the same CoNS identified in the blood culture of a given
patient. Outcomes were non-resolved infection (i.e. either presence of prolonged bacteremia or symptoms
attributed to CoNS-CRBSI > 2 days after catheter removal), recurrence, mortality and length of hospitalization after
catheter removal. We compared outcomes between a group with antibiotic treatment prescribed according to
current IDSA guidelines (≥5 days, “treatment” group) and a “no-treatment” group.
Results: Our study population comprised 184 CoNS-CRBSI episodes. Seventy-six percent received antibiotic treatment
≥5 days, while 17% did not receive therapy. Non-resolved infections were absent from the patients who did not receive
antibiotics. Severe neutropenia, hematologic cancer and immunosuppression were significantly more frequent in the
treatment group. The subgroup analysis with 32 matched pairs showed no significant difference in frequency of
non-resolved infection (0% in the no-treatment vs 15.6% in the ≥5 days treatment group, p = 0.06). The
remaining outcomes were similar in the two groups.
Conclusions: Our findings indicate that withholding antimicrobial therapy in CoNS-CRBSI is neither associated
with short-term complications nor with long-term recurrences.
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Catheter-related bloodstream infections (CRBSI) are the
leading subset of hospital-acquired bloodstream infections
(BSI) [1]. In Europe, BSI can be found in 1–3.1 cases per
1000 patient-days, 60% of which are catheter-associated
[1, 2]. Coagulase-negative staphylococci (CoNS) are the
most frequent etiology of BSI, especially in the setting of* Correspondence: niccolo.buetti@gmail.com
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bacteremia increase the duration of hospitalization, inten-
sive care unit (ICU) length of stay, morbidity and therapy-
related costs [4–6]. However, CoNS are considered
low-virulence microorganisms and data on outcomes in
terms of mortality due to these infections have been con-
flicting [5, 7, 8].
Few studies have examined the role of antibiotic treat-
ment in CoNS bacteremias. The heterogeneity of these
studies precludes any conclusion regarding efficacy. A
small study suggested that early antimicrobial treatment
might reduce the clinical impact of CoNS-CRBSI [5],le is distributed under the terms of the Creative Commons Attribution 4.0
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adequate antibiotics was irrelevant for outcomes [9]. An-
other recent analysis postulated that adequate empirical
therapy is not a requirement as long as the primary
focus is removed [7]. Current guidelines question the
need for treating these infections [10–12]. In particular,
for uncomplicated CoNS-CRBSI, the Infectious Dis-
eases Society of America (IDSA) guideline recommends
antibiotic treatment for 5–7 days in the setting of cath-
eter removal [10]. However, the same guideline high-
lights that some experts recommend no antibiotic
therapy in patients without intravascular prosthetic ma-
terial unless fever and/or bacteremia persist after cath-
eter withdrawal, thus leaving the choice to treat or not
to treat these infections open [10]. To our knowledge,
there has never been a direct comparison of clinical
outcomes in patients with CoNS-CRBSI treated with or
without antibiotic agents. The main objective of this
study was to elucidate the role of systemic antibiotic
therapy in the setting of catheter removal in adult pa-
tients with CoNS-CRBSI.
Methods
Study design and population
We performed a retrospective cohort study on patients
with CoNS-CRBSI admitted to Bern University Hospital,
a 950-bed tertiary care hospital in Bern, Switzerland.
Patients with CoNS-CRBSI were identified by match-
ing positive blood cultures and catheter tip data ex-
tracted from the clinical microbiology lab database at
the University of Bern. The inclusion criteria for this
study were the following: (1) age ≥ 18 years, (2) a re-
moved short- or long-term intravascular catheter with a
positive quantitative catheter tip culture, (3) the same
CoNS (with an identical antibiogram) isolated from a
blood culture drawn 7 days before to 2 days after cath-
eter removal and (4) admission to the hospital between
1 January 2008 and 31 December 2016. Patients with
Staphylococcus lugdunensis infection were excluded.
Episode definition
In general, an episode of CoNS-CRBSI had to fulfill the
IDSA criteria for definite CRBSI [10]: the same CoNS
grows from at least 1 percutaneous blood culture and
from the catheter tip, with a bacterial count of ≥103
colony forming units (CFU) [13]. Moreover, patients
having solely positive blood cultures drawn from the
catheter hub were only included if (1) local symptoms
were documented (e.g., redness or swelling) or (2) sys-
temic symptoms (e.g., fever or chills) without another
clinical focus were observed, thus qualifying at least for
a complicated “exit-site infection” or “possible CRBSI”
[10]. CRBSI episodes diagnosed by differential time-to-
positivity were not considered for this analysis, ascatheter removal was a selection criterion for our study.
Moreover, additional culture tip reports of another
catheter tip with CoNS in the same patient within 7
days after catheter removal were interpreted as dupli-
cate and therefore excluded.Clinical, catheter and microbiological data
Data on included patients were obtained through review of
their electronic medical records using a standardized data
collection tool. For each episode demographic features, site
of CRBSI onset, department at time of onset, underlying
chronic diseases including the Charlson Comorbidity Index
(CCI) [14] and immunosuppression (due to medication,
chemotherapy or illness), and presence of orthopedic hard-
ware or intravascular prosthetic material (other than intra-
vascular catheters) were recorded. Clinical, catheter and
microbiological data collected included: local exit-site in-
fection signs, systemic symptoms (e.g., fever), severe neu-
tropenia (leucocyte count < 0.5 G/L), type of catheter,
catheter site and dwell-time, number of blood cultures
drawn during an episode, number of positive blood cul-
tures and resistance patterns of CoNS.
The antibiotic therapy was considered adequate if it
included at least one antibiotic (e.g., vancomycin) to
which the isolate was susceptible and the treatment was
initiated no later than 48 h after catheter removal. In a
subanalysis, we compared episodes treated according to
current guidelines [3, 10–12, 15] versus episodes with-
out antibiotic treatment.Follow-up and clinical outcomes
The patient charts during hospitalization and after cath-
eter removal were carefully reviewed. All microbiological
data of a patient with CoNS-CRBSI were reviewed for a
12-month follow-up period.
It is still debated if mortality represents a reasonable
outcome measure for CoNS-CRBSI. In contrast to S.
aureus and Gram-negative bacteremia [16], there is no
standardized definition in the literature for treatment
success of these infections. Therefore, we modified a
previously used definition to determine the primary out-
come [17]: A non-resolved infection was defined as pro-
longed bacteremia (persistence of positive blood culture
with CoNS) or the presence of symptoms attributed to
CoNS-CRBSI (e.g., septic thrombosis, abscess) starting
more than 2 days after the catheter removal.
Secondary outcomes were hospital mortality, ICU ad-
mission during an episode, length of hospital stay after
catheter removal, mortality during follow-up and recur-
rence. Recurrence was defined as the occurrence of the
same CoNS (bacteremia or growth of CoNS in a sterile
site), within 1 week to 12 months after the date of the
initial bacteremia or until death (modified from Raad
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attributed to the antibiotic therapy.
The study was approved by the regional ethics com-
mittee (project number 2017–01827).
Statistical analysis
Group comparisons for continuous variables were car-
ried out using the Wilcoxon rank test, whereas for cat-
egorial variables the χ2 or Fisher’s exact test were used.
As primary analysis model, we fitted logistic regression
models with the dependent variable being the presence
of non-resolved infection, and independent variables
treatment group (antibiotic treatment ≥5 days vs no
treatment), an indicator variable for age group, gender,
CCI, catheter type, department, severe neutropenia dur-
ing the episode, fever, and exit-site infection signs.
We performed a post-hoc subgroup analysis to attempt
to adjust for inherent imbalance between the patient
populations in the two groups. We used both inverse
probability weighting (results not shown) and propensity
score matching to create a subgroup with 32 matched
pairs, 32 with treatment and 32 without treatment. To
calculate the scores, we fitted a logistic regression model
with treatment group as dependent variable, and an ex-
tended set of independent variables to enable us to use
all available information for the matching process. We
then used nearest neighbor matching to determine the
closest pairs. We visually checked the appropriateness of
the pairings by plotting the first two principal compo-
nents from a principal components analysis using the
same extended set of covariates (see Additional file 1:
Figures S1-S2). Once this process was complete, weFig. 1 Data sources. CoNS, coagulase-negative Staphylococci; CFU, colonyagain compared the groups using both descriptive statis-
tics and by fitting the primary analysis model to this
subgroup. Throughout, p-values < 0.05 were considered
statistically significant. All analyses were conducted
using SPSS (Version 25) or R (Version 3.4.2).
Results
During the study period, a total of 3′443 positive cath-
eter tips and 3′246 positive blood cultures with CoNS
were identified (see Fig. 1). Of these, 435 patients pre-
sented a concurrent bacteremia with the same CoNS
identified 7 days before to 48 h after catheter removal.
Eighty-four CoNS episodes were excluded because they
revealed different resistance patterns, 78 were duplicates
and 73 had microbial counts per catheter segment that
were considered too low. Our study population thus
comprised 184 CoNS-CRBSI episodes.
Patient characteristics and antibiotic therapy
The clinical characteristics of patients with CoNS-
CRBSI (n = 184) are illustrated in Table 1. The median
age was 61 years and patients were predominantly male
(70%). Ninety-six percent (177) of CoNS-CRBSI were
hospital-acquired; 41% (75) and 21% (38) were detected
in the hemato-oncological and internal medicine depart-
ments, respectively. Comorbidities such as malignancy
(109, 59%), immunosuppression (98, 53%) and diabetes
mellitus (40, 22%) were frequently encountered. The
mean Charlson Comorbidity Index was 4 (range 0–12).
Forty-nine patients (27%) had orthopedic hardware or
intravascular prosthetic material in place at the time of
the index hospital admission. Of the 184 patients withforming units









Age, years, median (IQR) 61 (51–67) 62.5 (51–67.5) 57.5 (52–63) 0.254
Sex, male 128 (70%) 96 (69%) 24 (75%) 0.616
BMI, kg/cm2, median (IQR) 26 (22–30) 26 (22–30) 25 (22–28.5) 0.535
Days in hospital, median (IQR) 29.5 (21–44) 31 (22–44) 28 (20–53.5) 0.783
Hospital-acquired CRBSI 177 (96%) 134 (96%) 32 (100%) 0.510
Department at time of diagnosis
ICU 37 (20%) 24 (17%) 10 (31%) 0.118
Surgery 34 (19%) 26 (19%) 8 (25%) 0.563
Internal medicine 38 (21%) 22 (16%) 12 (38%) 0.011
Hemato-oncology 75 (41%) 68 (49%) 2 (6%) < 0.001
Comorbidities
Malignancy 109 (59%) 91 (65%) 11 (34%) 0.003
Hematologic cancer 82 (45%) 74 (53%) 2 (6%) < 0.001
Solid cancer 27 (15%) 17 (12%) 9 (28%) 0.045
Immunosuppression 98 (53%) 85 (61%) 5 (16%) < 0.001
Chronic pulmonary disease 22 (12%) 15 (11%) 4 (13%) 1.000
Congestive heart failure 14 (8%) 10 (7%) 4 (13%) 0.521
Renal failure 22 (12%) 11 (8%) 7 (22%) 0.044
Cerebrovascular disease 11 (6%) 10 (7%) 1 (3%) 0.662
Diabetes mellitus 40 (22%) 28 (20%) 10 (31%) 0.251
CCI, median (range) 4 (0–12) 4 (0–12) 4 (1–10) 0.609
Any surgical treatment 74 (40) 52 (37%) 18 (56%) 0.074
Orthopedic hardware or intravascular
prosthetic material
Any device 49 (27%) 40 (29%) 8 (25%) 0.851
Orthopedic hardware 25 (14%) 19 (14%) 5 (16%) 0.984
Intravascular prosthetic material 25 (14%) 21 (15%) 4 (13%) 0.933
Clinical findings
Exit-site infection signs 64 (35%) 56 (40%) 3 (9%) 0.002
Fever (> 38.2 °C) 130 (71%) 107 (76%) 17 (53%) 0.015
Septic shock 4 (2%) 3 (2%) 0 (0%) 0.931
Severe neutropenia° 78 (42%) 71 (51%) 1 (3%) < 0.001
Catheter characteristics
Short-term catheter 170 (92%) 129 (92%) 30 (94%) 1.000
CVC 150 (82%) 116 (83%) 25 (78%) 0.709
Dwell time, median (IQR) 12 (9–17) 12 (9–17) 14 (9.5–20) 0.455
Long-term catheter 14 (8%) 11 (8%) 2 (6%) 1.000
Catheter site: jugular vein 138 (75%) 103 (74%) 26 (81%) 0.497
Microbiological data
Positive blood cultures, median (IQR) 2 (1–3) 2 (2–3) 1 (1–2) < 0.001
Total of blood cultures drawn,
median (range)
4 (3–7) 5 (3–7) 2.5 (2–5) 0.001
≥ 10′000 CFU on catheter tipª 124 (67%) 93 (66%) 22 (69%) 0.965
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CoNS resistant to oxacillin 143 (78%) 104 (74%) 30 (94%) 0.031
Antimicrobial therapy
Vancomycin 135 (73%) 126 (90%) 0 (0%)
Duration of adequate therapy,
median (IQR)
10 (5–15) 13 (8–18) 0 (0)
Abbreviations: IQR interquartile range, BMI body mass index, ICU intensive care unit, CCI Charlson comorbidity index, CVC central venous catheter, CFU colony
forming units
All values expressed as no. (%), unless otherwise indicated.*including all patients with ≥1 day treatment or no treatment. ° Severe neutropenia was defined as a
leucocyte count < 0.5 G/L ª the remaining patients had a 1′000 CFU growth on their removed catheter tips
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(64) presented local signs and 42% (78) were severely
neutropenic. Ninety-two percent of catheters (170) were
short-term intravascular catheters, most of them CVCs
(150, 82%).
Figure 2 shows the distribution of treatment duration
in our study group. Eighty-three percent of patients
(152) received adequate antibiotic therapy (Additional
file 1: Table S1) and 76% (140) were treated according to
the current IDSA guidelines (i.e., at least 5–7 days). The
median duration of treatment was 10 (IQR, 5–15) days.
Vancomycin was the most frequently administered ad-
equate antibiotic agent (135, 73%).
Patients without antibiotic therapy and comparison with
patients who received treatment ≥5 days
Two groups of patients were created, one that received
adequate therapy for ≥5 days and the other without anti-
biotic therapy. Among patients without antibiotic treat-
ment (32, 17%, “no treatment” group in Table 1), CRBSI
were most frequently observed in internal medicine de-
partments (12, 38%). The median Charlson ComorbidityFig. 2 Distribution of the duration of antibiotic therapy (n = 184)Index was 4, 34% (11) of patients had a malignancy, and
25% (8) had orthopedic hardware or intravascular pros-
thetic material in situ on admission. Severe neutropenia
was infrequently observed (1, 3%) in this group.
In general, the two groups presented similar baseline
characteristics (Table 1). Similar percentages regarding
the presence of prosthetic material and catheter charac-
teristics were observed in both groups. However,
CoNS-CRBSI in the “no treatment” group were less fre-
quently observed in the hemato-oncologic department
(6% vs 49% in the “treatment” group, p < 0.001), had less
often hematologic cancer (6% vs 53%, p < 0.001), were
less severely neutropenic (3% vs 51%, p < 0.001), and
presented both fewer local (9% vs 40%, p = 0.002) and
systemic signs (53% vs 76%, p = 0.015).
Evaluation of outcomes
The mean follow-up time was 234 (SD ±155.1) days
(Table 2). Of the 184 patients with CoNS-CRBSI, a
non-resolved infection was observed in 30 patients
(16%), with septic thrombosis being the most frequently
observed complication (25, 14%). Recurrences were









Non-resolved infection 30 (16%) 29 (21%) 0 (0%) 0.010
Septic thrombosis 25 (14%) 24 (17%) 0 (0%) 0.025
Prolonged bacteremia 4 (2%) 4 (3%) 0 (0%) 0.751
Abscess 2 (1%) 2 (1%) 0 (0%) 1.000
Secondary oucomes
Recurrence (bacteremia) 8 (4%) 8 (6%) 0 (0%) 0.358
ICU admission 18 (10%) 15 (11%) 1 (3%) 0.111
Days to discharge,
median (IQR)
13 (7–21) 15 (8–21) 11.5 (5–32) 0.253
Hospital mortality 22 (12%) 12 (9%) 6 (19%) 0.169
Mortality during follow-up 38 (21%) 26 (19%) 8 (25%) 0.563
Side effects 3 (2%) 3 (2%)
Days of follow-up,
mean (±SD)
234.2 (±155.1) 241.2 (±152.3) 232.4 (±161.2)
Abbreviations: ICU intensive care unit, IQR interquartile range, SD standard deviation
All values expressed as no. (%), unless otherwise indicated. aincluding all patients with ≥1 day treatment or no treatment
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prosthetic material infections with CoNS were observed
during the entire follow-up. Focusing on raw group
proportion comparisons, none of the patients without
antibiotic therapy experienced a non-resolved infec-
tion (0% infections in the no-treatment group vs 22%Table 3 Group comparisons following the nearest neighbor
matching process





Age mean (±SD) 58.0 (±15.7) 57.3 (±11.5) 0.892
Sex (mean) 26 (81%) 24 (75) 0.762
ICU 11 (34%) 10 (31%) 1.000
Internal medicine 11 (34%) 12 (38%) 1.000
Malignancy 13 (41%) 11 (34%) 0.796
Hematologic cancer 3 (9%) 2 (6%) 1.000
Immunosuppression 5 (16%) 5 (16%) 1.000
Renal failure 5 (16%) 7 (22%) 0.749
CCI, mean 4.3 4.1 0.109




10 (31%) 8 (25%) 0.781
Fever (> 38.2 °C) 19 (59%) 17 (53%) 0.801
Catheter type: short-term 29 (91%) 30 (94%) 1.000
Primary endpoint
(Non-resolved Infection)
5 (16%) 0 (0%) 0.062
Abbreviations: SD standard deviation, ICU intensive care unit, CCI Charlson
Comorbidity Index
All values expressed as no. (%), unless otherwise indicatedin those who received treatment according to guide-
lines, p = 0.01). The subgroup analysis utilized propen-
sity scores and nearest neighbor matching to compare
groups of similar patients with and without antibiotic
treatment. The rates of outcomes approached each
other after propensity score matched adjustment in terms
of the non-resolved infection (0% vs 16%, p = 0.06; Table 3
and Additional file 1: Figures S1-S2). The majority of the
32 patients chosen for these analyses were non-neutropenic
(31, 96.9%).
On the basis of univariate analyses, the secondary
outcomes were similar in the two comparison groups
(Table 2). In particular, no recurrence was observed
in the “no treatment” group. Side effects due to anti-
biotic therapy were observed in only three of 32 pa-
tients (2%).
Discussion
Our findings indicate that patients not receiving antibi-
otics for CoNS-CRBSI after catheter removal experience
a similarly low rate of complications as patients receiv-
ing ≥5 days of antibiotic therapy. This conclusion may
probably only be applied to non-neutropenic patients
given our results, which are supported by a neighbor
analysis and a principal components analysis for the pri-
mary outcome.
To date, there are no well-designed and adequately pow-
ered trials to compare the role of antibiotic therapy in
CoNS-CRBSI following catheter removal. Accordingly,
practice often relies on prescriber preference and individual
experience. The current IDSA guideline on catheter-related
infections suggests prescribing antibiotic therapy for at least
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reviews support similar recommendations [3, 11, 12, 15].
Alternatively, patients with CoNS-CRBSI can be followed
without antibiotic administration if the patients have nei-
ther orthopedic hardware nor intravascular prosthetic ma-
terial in place. This strategy is based on expert opinion
[10] and current recommendations (2009) are not based
on relevant clinical evidence. Unfortunately, little progress
has been made since that time to improve the evidence
base regarding antibiotic administration for CoNS-CRBSI.
In a retrospective study, Raad et al. concluded that
prolonged antibiotic treatment was not associated with
better resolution of bacteremia or significantly lower rate
of recurrence. However, in Raad’s study patients without
antibiotics were not separately analyzed [17]. In an ob-
servational case-control study including patients with
and without CoNS bacteremia, Molina et al. found an
association between mortality and delay of appropriate
antibiotic treatment. However, worse outcomes related
to inappropriate empirical treatment were observed irre-
spective of whether patients had CoNS-BSI or not. A
sub-analysis performed in only those patients with CoNS
bacteremia showed that appropriate empirical treatment
or delay of appropriate treatment did not affect out-
comes [5]. Recently, Park et al. concluded that in-
appropriate empirical therapy does not lead to poor
outcomes in CoNS-CRBSI bacteremia [7]. The reten-
tion of an eradicable focus such as intravascular cath-
eter, however, might adversely affect outcomes in
CoNS bacteremia. Moreover, that study population
also included bacteremic patients without a CoNS-
CRBSI thus limiting the generalizability of their results
to intravascular catheter infections [7]. Of note, all
these studies included patients with catheter retention
and none compared patient characteristics between
the different groups in the setting of catheter removal
as we did here. Our study clearly supports the option
of following patients with CoNS-CRBSI without ad-
ministering antibiotic treatment by providing the first
direct comparison with the standard approach, anti-
biotic treatment. Interestingly, the presence of foreign
bodies (e.g., orthopedic hardware or intravascular
prosthetic material) did not influence the rate of late
recurrences. To our knowledge, only one study has
ever assessed the occurrence of recurrent
CoNS-CRBSI [17], revealing that patients with cath-
eter retention were more likely to suffer from infec-
tion recurrence. However, 1) only bacteremias were
reviewed without considering other metastatic foci,
and 2) the role of antibiotics was not assessed in a
sub-analysis. Reducing antibiotic use, in particular
vancomycin, may be effective in decreasing both sev-
eral adverse effects in the short term [18, 19] and anti-
biotic resistance in the long term [20, 21].Our study has several limitations. This was a small,
retrospective, single-center study and the results may
not be applicable to patients with severe neutropenia.
However, the population included in the nearest neigh-
bor analysis also included very ill patients and therefore
our conclusions may be applied to a variety of patient
settings. Moreover, patients receiving ≥5 days of
antibiotic therapy showed higher risk of complications.
Following matching, this difference was reduced, with-
out statistical significance at the 5% level. The remaining
difference might be explained by the presence of un-
measured confounders. Furthermore, patients without
significant growth of CoNS on the catheter tip as well as
CoNS-CRBSI diagnosed by differential time-to-positivity
(without tip culture), were not included, which may have
led to an underestimation of the total burden of CoNS-
CRBSI. On one hand, no molecular typing was per-
formed for recurrences, which can lead to overesti-
mation of this specific outcome; on the other hand,
patients were not on defined clinical and follow-up pro-
tocols, which may have led to an increased number of
lost-to-follow-up patients.Conclusions
These limitations notwithstanding, our study clearly sug-
gests that managing CoNS-CRBSI in non-neutropenic
patients without clinical evidence of local symptoms
solely with catheter removal appears to be an option
with neither short-term complications nor long-term re-
currences, even if orthopedic hardware or intravascular
prosthetic material remain in place. To verify our find-
ings and ensure patient safety, further investigations in
prospective randomized trials are needed.Additional file
Additional file 1: Figure S1 Distribution of propensity scores post
matching process. Figure S2. Plot of the first two principal components
with the full data set to determine the appropriateness of the matches
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